News and events from NCI-funded research and programs
News & Events
Recent News Releases
New approach may increase the effectiveness of T-cell-based immunotherapy treatments against solid tumors.
NIH immunotherapy pioneer Steven Rosenberg awarded nation’s highest honor for technology and innovation
Steven A. Rosenberg, M.D., Ph.D., has been awarded the National Medal of Technology and Innovation by President Biden. It is the nation's highest honor for technological achievement.
Annual Report to the Nation Part 2: New cancer diagnoses fell abruptly early in the COVID-19 pandemic
New diagnoses of six major cancer types fell in the early part of the pandemic, according to findings from part 2 of the latest Annual Report to the Nation on the Status of Cancer.
NCI unveils comprehensive proteogenomic dataset to help cancer researchers unravel molecular mysteries
NCI’s Clinical Proteomic Tumor Analysis Consortium releases proteogenomic dataset to accelerate cancer discoveries.
An NCI study shows that cell division can be interrupted by withdrawing growth-promoting signals early on in the process.
NCI has awarded $50 million to establish five new centers to study interventions for improving cancer outcomes in persistent poverty communities.
ComboMATCH will consist of numerous phase 2 cancer treatment trials that aim to identify promising drug combinations that can advance to larger, more definitive clinical trials.
NCI study outlines opportunities to achieve President Biden’s Cancer Moonshot goal of reducing cancer death rates in the United States
A new study has outlined opportunities for achieving President Biden and First Lady Biden’s Cancer Moonshot goal of reducing the cancer death rate by at least 50% over the next 25 years.
Pragmatica-Lung Study, a streamlined model for future cancer clinical trials, begins enrolling patients
NCI has helped launch the Pragmatica-Lung Study, a phase 3 randomized clinical trial of a two-drug combination to treat patients with advanced non-small cell lung cancer. The simplified trial design aims to increase accessibility for participants.
NCI study finds that immunotherapy substantially increases survival of people with lymphomatoid granulomatosis
An NCI study shows that people with low-grade lymphomatoid granulomatosis who are treated with interferon alfa-2b, a type of immunotherapy, can live for decades after diagnosis.